FRESENIUS SE & CO. KGAA

(FRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius Kabi is committed to achieving Net Zero emissions by 2045

01/17/2022 | 09:16am EDT

The UK Government amended the Climate Change Act 2008 in 2019 introducing a target of at least a 100% reduction in the net carbon account (reduction of greenhouse gas emissions compared to 1990 levels) by 2050. This is the Net Zero Target.

Fresenius Kabi Limited (Fresenius Kabi) is part of the Fresenius Kabi global healthcare organisation that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi is a division of the healthcare group Fresenius SE & Co. KGaA. In the UK FHC (Holdings) Limited is the holding company to two subsidiaries: Fresenius Kabi and Calea UK Limited (Calea). These companies are healthcare companies involved in producing pharmaceutical products, controlled drugs, nutritional feed and nursing services. Both companies operate out of two sites in Runcorn; these consist of warehouse space, offices, and an aseptic compounding unit. Fresenius Kabi is a large unquoted company under the Streamlined Energy and Carbon Reporting regulations by virtue of meeting both financial and employee thresholds.

Fresenius Kabi has reported most of its scope 1 and scope 2 emissions for the 2020 period under these regulations. This plan covers all scope 1 and 2 emissions in line with the GHG Protocol Corporate Standard and Action Note PPN 06/21. Work is currently being done to map scope 3 emissions and an interim report will follow.

Contact:

Phone: 01928 533533

Postal Address

Fresenius Kabi Ltd and Calea

Cestrian Court

Eastgate Way, Manor Park

Runcorn, Cheshire

WA7 1NT

United Kingdom

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about FRESENIUS SE & CO. KGAA
05:37aFRESENIUS SE : Deutsche Bank remains Neutral
MD
05/25FRESENIUS SE : JP Morgan remains Neutral
MD
05/24Fresenius Kabi - EuroPN Study, New clinical data on medical nutrition therapy in critic..
AQ
05/20FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by persons
EQ
05/19FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by persons
EQ
05/16FRESENIUS SE & CO. KGAA : Ex-dividend day for final dividend
FA
05/16FRESENIUS SE & CO. KGAA : Ex-dividend day for final dividend (optional)
FA
05/13TRANSCRIPT : Fresenius SE & Co. KGaA - Shareholder/Analyst Call
CI
05/13FRESENIUS SE : JP Morgan reiterates its Neutral rating
MD
05/12FRESENIUS SE : DZ Bank reaffirms its Buy rating
MD
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Financials
Sales 2022 40 073 M 42 790 M 42 790 M
Net income 2022 1 843 M 1 968 M 1 968 M
Net Debt 2022 22 014 M 23 506 M 23 506 M
P/E ratio 2022 9,62x
Yield 2022 3,05%
Capitalization 17 816 M 19 024 M 19 024 M
EV / Sales 2022 0,99x
EV / Sales 2023 0,91x
Nbr of Employees 317 242
Free-Float 73,4%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | FRE | DE0005785604 | MarketScreener
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 31,90 €
Average target price 44,16 €
Spread / Average Target 38,4%
EPS Revisions
Managers and Directors
Stephan Sturm Chairman-Management Board & CEO
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Michael Albrecht Independent Member-Supervisory Board
Konrad K÷lbl Independent Member-Supervisory Board